Ad
related to: ezetimibe drugbank 10 ml
Search results
Results From The WOW.Com Content Network
Within 4–12 hours of the oral administration of a 10-mg dose to fasting adults, the attained mean ezetimibe peak plasma concentration (C max) was 3.4–5.5 ng/ml. Following oral administration, ezetimibe is absorbed and extensively conjugated to a phenolic glucuronide (active metabolite).
Ezetimibe/rosuvastatin, sold under the brand name Ridutrin among others, is a combination medication used to treat high cholesterol. [6] [7] In some countries it is sold as a kit or a pack containing two distinct pills. [8] [9] The combination was approved for medical use in the United States in March 2021. [4]
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug. In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [ 1 ]
With median follow-up of 6 years, simvastatin+ezetimibe was found to reduce the primary outcome of CV mortality, major CV event, or nonfatal stroke (34.7% vs. 32.7%; P=0.016; NNT 50 per 7 years or NNT 350 per 1 year ). There was no reduction in all-cause or CV mortality with simvastatin+ezetimibe, though there was a reduction in MI and stroke. [6]
It has been tested in clinical trials as single treatment and in combinations with atorvastatin, ezetimibe and fenofibrate. [ 4 ] [ 5 ] The US Food and Drug Administration (FDA) approved lomitapide in December 2012, as an orphan drug to reduce LDL cholesterol , total cholesterol , apolipoprotein B , and non-high-density lipoprotein (non-HDL ...
Bempedoic acid/ezetimibe, sold under the brand name Nexlizet among others, is a fixed-dose combination medication used for the treatment of high cholesterol. [ 1 ] [ 3 ] It is a combination of bempedoic acid and ezetimibe .
Hyzetimibe is a pharmaceutical drug that inhibits cholesterol absorption. [1] [2] It targets the NPC1-like intracellular cholesterol transporter 1.[2]It reduces plasma levels of low-density lipoprotein cholesterol (LDL-C) by blocking the Niemann-Pick C1-like 1 protein, a transporter mainly found in the intestine that allows dietary cholesterol to enter the body from the intestinal lumen.
Overall, the dose range from 10 mg to 160 mg of buntanetap is well tolerated and generally adopted in clinical uses. With higher doses, supralinear increase of plasma levels was shown, indicating the saturable metabolism, which is a factor related to toxicity.